INTRODUCTION

26
It is widely recognized that omega-3 (n-3) polyunsaturated fatty acids 27 (PUFAs), in particular eicosapentaenoic acid (EPA; 20:5n-3) and 28 docosahexaenoic acid (DHA; 22:6n-3), play an important protective role in 29 metabolic, cardiovascular, developmental, and cognitive health. [1] [2] [3] EPA and DHA 30 are endogenously produced from the essential alpha-linolenic acid (ALA; 18:3 n- 31 3) in a well-characterized enzymatic pathway (Figure 1 ). [4] The conversion occurs 32 by a sequential insertion of new carbons and double-bonds within the ALA chain, 33 for which the enzymes encoded by the genes elongase 2 and 5 (ELOVL2 and 34 ELOVL5, respectively) and fatty acid desaturase 1 and 2 (FADS1 and FADS2, 35 respectively) play a crucial role. [4, 5] The same pathway is responsible for 36 producing arachidonic acid (ARA; 20:4n-6) from its essential precursor linoleic 37 acid (LA; 18:2n-6). This pathway is considered to mainly operate in the liver. 38 However, human intestinal cell lines have been shown to desaturate and elongate 39 LA and ALA to produce longer chain, more unsaturated derivatives. [6] Although 40 evidence of the contribution of the intestine to production of the bioactive n-6 and 41 n-3 PUFAs in humans is lacking, we suggest that the intestine may be an applied to assess the amount and frequency of fish and soybean oil ingestion as 100 the main dietary sources of n-3 and n-6 PUFAs, respectively. 101 jejunum and ileum) were collected by double-balloon enteroscopy (DBE) and 105 immediately immersed in liquid nitrogen before transfer to a -80 o C freezer. The 106 biopsy procedure was performed through oral access and under deep sedation 107 preoperatively and again 3 months postoperatively, as described elsewhere. [16] 
108
The site of preoperative biopsies was highlighted with India ink SPOT TM to guide 
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Intestinal biopsies were submitted to RNA extraction using RNasy Plus kit according to the method of Folch et al. [18] Fatty acid methyl esters were prepared 156 by incubation with 140 g/L of boron trifluoride in methanol at 80°C for 60 min.
157
Subsequent to the extraction process, the fatty acid methyl esters were dried and analyze changes in the expression of genes encoding GI hormones related to 168 postoperative glycemic homeostasis. [14] The sample size was calculated using Table 2 shows data on total PUFAs, fish and soybean oil intakes and the 
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The ratio of ARA to EPA was lower at preoperative than 3 and 12 months after endogenous metabolism. [19, 20] Our patients presented a comparatively very low 265 median of EPA plus DHA (near to 1.5%) at all the studied periods, highly 266 suggestive of a systemic depletion of these PUFAs even before surgery.
267
Although high ALA intake has been shown to increase the biosynthesis of nutritional deficiencies [11, 12] , the impact on n-3 PUFA status remains poorly 277 explored. We were able to identify only one previous clinical trial on this topic, 278 which reported changes in the proportion of systemic PUFAs 1 and 6 months 279 following RYGB. [26] Although the authors found no changes in ALA, a persistent 280 decreased EPA and transient increased ARA and DHA proportions along with a 281 low but stable intake of n-3 PUFAs from the preoperative period were observed 282 after the surgical procedure. [26] These findings on proportions of PUFAs are quite of dietary EPA to DHA may be maintained, as the expression of ELOVL2 was 303 unchanged and even slightly but not significantly increased. [28] This also would 304 use EPA, further contributing to its lower plasma concentration.
305
To our knowledge, this is the first study showing a downregulation of the 306 gene encoding the FADS1 enzyme at multiple intestinal sites following RYGB.
307
One would expect increased ALA and decreased plasma EPA and DHA levels variations in its cluster are associated with the systemic ARA depletion. [29] In 318 common with these findings, instead of observing a concomitant decrease of 319 intestinal expression of FADS1 and systemic ARA levels, the plasma proportion 320 of this PUFA was increased in our patients 3 months after RYGB, compared to 321 the preoperative period and 12 months postoperatively. A transiently increased 322 proportion of ARA after RYGB observed in our study and in other trial may be as a result of the surgery causing weight loss, with high triglyceride breakdown. [26] Particularly, ARA (n-6 PUFA) has pro-inflammatory and detrimental lipogenic 348 properties, while the EPA and DHA (n-3 PUFAs) have opposite effects. [34] 
349
In accordance with their biological properties, high n-6 fatty acid levels are 350 associated with an increased risk of obesity, whereas a high concentration of n-351 3 fatty acids in phospholipids is associated with reduced risk. [35] The post- might create an unfavorable systemic PUFA profile. [36] [37] [38] 
357
RYGB has shown metabolic effects that counteract some obesity-358 associated comorbidities. [39] In particular, obese patients with type 2 diabetes can 359 experience glycemic homeostasis early after the procedure, but not all of them 360 achieve the postoperative remission of the disease and some can experience its 361 relapse longer term. [40] [41] [42] [43] It is possible that the unfavorable PUFA profile induced 362 by RYGB may impair the achievement and maintenance of the metabolic benefits 363 expected to be induced surgically.
364
It has been consistently demonstrated that higher plasma levels of EPA 365 and DHA are crucial in maintaining positive health outcomes by preventing and 366 treating metabolic and inflammatory disorders. [3, [44] [45] [46] Large observational studies 367 have been homogenous in terms of these findings, with systematic reviews and 368 meta-analyses showing that higher consumption of fish and higher dietary or 369 plasma levels of n-3 PUFAs are associated with a lower risk of chronic disorders, 370 in particular of cardiovascular diseases. [47] [48] [49] [50] [51] All of these benefits may aid the recovery of obese patients undergoing RYGB and favor the postoperative 372 resolution of their obesity-related comorbidities. [52] 
373
We propose that n-3 PUFA supplementation may be required following 374 RYGB to counteract the surgery induced reduction in n-3 PUFA status. Notably, 375 according to our data, systemic n-3 PUFA depletion seems to occur before 376 RYGB, and therefore patients may benefit from supplementation before the 377 procedure. In a double blind randomized trial, the supplementation of n-3 PUFAs patients . [53] In another study, 4-weeks of preoperative supplementation with n-3
382
PUFAs reduced the liver volume of severely obese patients and facilitated the 383 access to the gastro-esophageal junction during laparoscopic RYGB surgery by 384 promoting an easy retraction of the left hepatic lobe. [54] 
385
Our study has some limitations. Although the seven-day nutritional record 386 showed a significant reduction in total PUFAs and fish intake in both 387 postoperative periods after RYGB, the individual intake of n-3 PUFAs (ALA, EPA, 
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